Evidence map›Paper›PMID 41125933›Full record

ArticleSurgical endoscopy2026

Advanced chronic kidney disease increases the odds of ERCP adverse events but not post-ERCP pancreatitis: a propensity-matched analysis of the US Collaborative Network.

Hussein Baydoun, Azizullah Beran, Daryl Ramai, Vikram R Rajagopalan, Aladdin Said Dahbour, Mina Batarseh, Ujwala Pamidimukkala, Eugene Nwankwo, Islam Mohamed, Clive Jude Miranda and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hussein BaydounDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Azizullah BeranDivision of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Daryl RamaiDivision of Gastroenterology and Hepatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Vikram R RajagopalanDivision of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Aladdin Said DahbourDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Mina BatarsehDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Ujwala PamidimukkalaDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Eugene NwankwoDivision of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA.
Islam MohamedDepartment of Medicine, Fairview Cleveland Clinic Hospital, Cleveland, OH, USA.
Clive Jude MirandaDivision of Gastroenterology, Creighton University Medical Center-Bergan Mercy, Omaha, NE, USA.
Hisham WehbeDivision of Gastroenterology, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA.
Oluwafisayo AdebiyiDivision of Nephrology, Indiana University School of Medicine, Indianapolis, IN, USA.
Indira Bhavsar-BurkeDivision of Gastroenterology and Hepatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
John J GuardiolaDivision of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Itegbemie ObaitanDivision of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. iobaitan@iu.edu.ORCID 0000-0001-5002-6821

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with chronic kidney disease (CKD) are at an increased risk choledocholithiasis, requiring intervention with endoscopic retrograde cholangiopancreatography (ERCP). Data on ERCP-related adverse events in this population is limited, hence this study.

methodsThis retrospective cohort study utilized the TriNetX database to assess the odds of ERCP-related adverse events in patients with stages 4 and 5 chronic kidney disease, as well as end-stage renal disease (ESRD) on dialysis. Primary outcomes were ERCP-related pancreatitis (PEP), bleeding, cholangitis, and perforation. Secondary outcomes were failure to extubate/new post-procedure intubation, intensive care unit (ICU) admissions, and all-cause mortality.

resultsAfter propensity score matching, our study included 4450 patients in the aCKD cohort and 4450 patients in the matched control cohort who underwent ERCP. Patients with aCKD had an increased odds of bleeding (OR 2.1, p < 0.001), cholangitis (OR 1.6, p < 0.001), ICU admissions (OR 2.2, p < 0.001), intubation (OR 3.0, p < 0.001) and mortality (OR 1.8, p < 0.001) compared to those with normal renal function. The odds of PEP (OR 1.1, p = 0.542) and perforation (OR 1.3, p = 0.528) were statistically similar between the two cohorts. No subgroup differences in ERCP-related AE were found except for increased ICU admissions odds in ESRD patients.

conclusionaCKD patients are a demonstrably high-risk group for certain ERCP-related AEs but not for PEP or perforation, a finding that may change the previous widespread perception of increased PEP risk in this population. Additional studies are needed to validate our findings and investigate potential interventions to improve clinical outcomes in this high-risk population.

Indexed as

Cholangiopancreatography, Endoscopic RetrogradeCholedocholithiasisPancreatitisPostoperative ComplicationsRenal Insufficiency, ChronicAgedCholangitisFemaleHumansKidney Failure, ChronicMaleMiddle AgedPropensity ScoreRetrospective StudiesUnited StatesChronic kidney diseaseEndoscopic retrograde cholangiopancreatographyEnd-stage renal diseasePost-ERCP pancreatitisPost-procedure bleeding; cholangitis

Identifiers

PMID41125933
PMCPMC12823648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.